Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus brevis SBC8803

What does the research say about Lactobacillus brevis SBC8803?

12 health outcomes synthesised

Research on Lactobacillus brevis SBC8803 has been conducted across 12 health outcomes, with the strongest evidence—though still low strength—supporting improved skin hydration, studied in 10 papers. Key trials used 25–50 mg/day for 8–12 weeks in adults with mild dry skin. Other areas of focus include sleep quality, inflammation, and body fat, all based on limited direct evidence.

Strongest evidence All 12 outcomes have low or very low evidence strength. The best-supported outcome is improved skin hydration, with 10 studies (all beneficial, small effect sizes). The only consistent effective dose reported is 25–50 mg/day from the primary randomized controlled trial. Improved sleep quality (7 studies, moderate effect) and reduced body fat (4 studies, small effect) also show consistent benefits, but the evidence base is small and subject to publication bias.

Mixed or weaker evidence Several outcomes rely on very low strength evidence, including intestinal barrier function (5 studies, all reviews), immune function (3 reviews), and alcohol-induced liver injury (3 animal/in vitro studies). None of these reached statistical significance in their primary analyses. Many syntheses note that effects may be smaller than the predominant direction suggests due to null-result publication bias.

Effective dose patterns Only one outcome—skin hydration—has a clearly reported dose range (25–50 mg/day). For most other outcomes (sleep, inflammation, fatigue, etc.), doses, forms, and durations were not consistently reported across studies, making cross-cutting dose comparisons impossible.

Population insights The studied populations are narrow and often healthy: adults with slightly elevated transepidermal water loss, healthy middle-aged Japanese women, obese individuals without comorbidities, and adults with elevated insomnia scores. No consistent benefit has been shown in deficient or diseased populations beyond these specific groups.

Notable caveats Virtually all syntheses flag publication bias (null studies less likely to be published). Many of the included papers are narrative reviews citing the same primary trials, so the true evidence base is narrower than the total paper count suggests. Statistical significance was rarely achieved, and most effect sizes are small. Direct evidence for Lactobacillus brevis SBC8803 specifically is often limited to one or two human trials; the rest involve other strains or preclinical models.

Frequently asked

  • What is Lactobacillus brevis SBC8803 good for according to research?
    Research suggests potential benefits for skin hydration (10 studies), sleep quality (7 studies), and body fat reduction (4 studies), all with consistent but small effects. However, the evidence strength is low overall, and many studies are reviews or indirect.
  • What dose of Lactobacillus brevis SBC8803 is typically used in studies?
    The only consistently reported dose comes from the primary skin hydration trial: 25–50 mg/day for 8–12 weeks. For other outcomes like sleep or inflammation, no specific effective dose was reported in the available syntheses.
  • Who benefits most from Lactobacillus brevis SBC8803?
    The research primarily involves healthy middle-aged adults, Japanese women with mild dry skin, and obese individuals without comorbidities. There is no strong evidence for benefits in diseased or deficient populations.
  • Are there caveats or limitations in the research on Lactobacillus brevis SBC8803?
    Yes. Publication bias is a major concern—null results are less likely to be published. Many studies are narrative reviews that cite the same primary trials, narrowing the evidence base. Most effects are small and often fail to reach statistical significance.
  • Does Lactobacillus brevis SBC8803 help with sleep quality?
    Seven studies report beneficial effects on sleep quality with moderate effect sizes, but only one study directly tested the strain (a pilot with 17 participants). The remaining studies involve other probiotics, limiting direct applicability.
  • Does Lactobacillus brevis SBC8803 help with body fat reduction?
    Four studies report beneficial effects, including a 2025 meta-analysis showing a small but statistically significant body fat reduction (MD –1.11 kg) in obese individuals. However, the evidence base is small and most studies are reviews.

  • Simple Slumbers

    By Unisom

    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $14.86
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out
Back to top